FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(The FASEB Journal. 2007;21:854.17)
© 2007 FASEB
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Rudkowska, I.
Right arrow Articles by Jones, P. J.
PubMed
Right arrow Articles by Rudkowska, I.
Right arrow Articles by Jones, P. J.

854.17

Non-responsiveness to plant sterol treatment and possible polymorphisms: ABCG5, ABCG8 and NPC1L1

Iwona Rudkowska1,2, Suhad S AbuMweis3, Catherine Nicolle4 and Peter JH Jones1

1 Richardson Centre for Functional Foods and Nutraceuticals, University of Manitoba, 196 Innovation Drive, Winnipeg, R3T 6C5, Canada,
2 Institute of Nutraceuticals and Functional Foods, 2440 Hochelaga, Québec, G1K 7P4, Canada,
3 School of Dietetics and Human Nutrition, McGill University, 21,111 Lakeshore Road, Ste-Anne-de-Bellevue, H9X 3V9, Canada,
4 Danone Research, Route Departementale 128, Palaiseau Cedex, 91767, France

ABSTRACT

Plant sterols (PS) have been shown to decrease low-density lipoprotein cholesterol (LDL-C); however, high variability of responsiveness of lipids levels to PS treatment has been observed. We hypothesized that common variants in ATP binding cassette protein G5 (ABCG5) and G8 (ABCG8) or Nieman-Pick C1-like 1 (NPC1L1) would underline these large inter-individual variations in the plasma lipids in response to PS treatment. Twenty-six hyperlipidemic subjects completed the randomized trial of three PS (1.6 g/d in low-fat yogurt) and control phase. Twenty-three subjects consistency lowered their LDL-C and total cholesterol (TC) during the three PS phases compared to control. Yet, three non-responders were identified as constantly failed to decrease both TC and LDL-C in all three PS phases vs. control. However, none of the polymorphisms tested: ABCG8 (V632A, D19H, T400K); ABCG5 (A478T, Q604E); and NPC1L1 showed an association between the top three responders and non-responders. Results indicate that non-responsive subjects to PS treatment may explain large heterogeneity in lipid data; however, no recognizable pattern in polymorphisms was detected. Still, their remains the possible link between other different or combination of haplotypes may demonstrate a non-response phenotype that may establish subjects for which PS treatment would be an ineffective therapeutic strategy.

Funding by Danone Research.





This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Rudkowska, I.
Right arrow Articles by Jones, P. J.
PubMed
Right arrow Articles by Rudkowska, I.
Right arrow Articles by Jones, P. J.